Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335605 · ClinicalTrials.gov registry record
Improving the Diagnosis of Common Variable Immune Deficiency
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 24
- Enrollment target
NCT03335605 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 24 participants.
The verdict
NCT03335605 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is an observational, case-control study with a single blood draw among two cohorts, patients with antibody deficiency (e.g., CVID) and healthy controls. Samples will be analyzed by mass cytometry (CyTOF) to examine the major signaling pathways of all circulating innate and adaptive immune cell types, as well as whole exome sequencing. The goal is to improve our general understanding of the human immune response to infections and the diagnosis of CVID.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03335605
The ClinicalTrials.gov registry entry for NCT03335605 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03335605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03335605 about?
NCT03335605 is a clinical study titled "Improving the Diagnosis of Common Variable Immune Deficiency". This is an observational, case-control study with a single blood draw among two cohorts, patients with antibody deficiency (e.g., CVID) and healthy controls. Samples will be analyzed by mass cytometry (CyTOF) to examine the major signaling pathways of all circulating innate and adaptive immune cell ...
What is the current status of trial NCT03335605?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2019-05-01. Estimated completion is 2022-06-01.
Who is sponsoring clinical trial NCT03335605?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.